Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 184Magnetic Resonance Spectroscopy 139Biopsy 102Immunoglobulin G 38Disulfides 38Cisplatin 37Nivolumab 36Platinum 35Paclitaxel 351,2-diaminocyclohexaneplatinum II citrate 35Radiation 34Cyclophosphamide 34Carboplatin 33Taxes 32Radiotherapy 28X-Rays 27pembrolizumab 26Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 21Gemcitabine 19Vincristine 18Prednisone 17Etoposide 17Leucovorin 16Cytarabine 16fludarabine 15durvalumab 15Phantoms, Imaging 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × pazopanib × 30 days × Clear all
NCT01575548 2026-05-29

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

National Cancer Institute (NCI)

Phase 3 Active not recruiting
129 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT01841736 2026-05-29

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡